A personalized monitoring strategy that integrates clinical assessment, imaging and fluid biomarkers holds the greatest promise for improving the detection of subclinical disease activity, refining risk stratification, and enabling more informed and individualized treatment decisions in contemporary MS care.
Föttinger et al. (Mon,) studied this question.